At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Avelumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Trial of Avelumab, an Anti-PDL1 Antibody, in Relapsed and Refractory Peripheral T-cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Avelumab for T-Cell Lymphoma Relapsed and T-Cell Lymphoma Refractory. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The AVAIL-T trial is a trial to find out how effective avelumab is at treating patients with primary T-cell lymphoma that is refractory to or has relapsed following initial treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartDec 2017
Primary CompletionJul 2020
Study CompletionJul 2021
TodayJul 2026
First PostedFeb 8, 2017
Enrollment StartDec 8, 2017
Primary CompletionJul 31, 2020
Study CompletionJul 27, 2021
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.4 years ago
Interventions
Avelumabdrug
anti-PDL1 antibody